Unique Pharmaceutical Laboratories Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 Mg Due to Potential Cross Contamination With Ranitidine
July 21, 2026
July 21, 2026
WASHINGTON, July 21 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following recall notice:
* * *
Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine
Summary
Company Announcement Date: July 18, 2026
FDA Publish Date: Ju . . .
* * *
Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine
Summary
Company Announcement Date: July 18, 2026
FDA Publish Date: Ju . . .